Transaction #6300 · Form 4 · 0000874716-25-000168
IDEXX LABORATORIES INC /DE · Exercise / conversion · Common Stock
IDEXX LABORATORIES INC /DE · Transacted November 7, 2025 · Filed November 10, 2025
What does this filing report?
An SEC Form 4 filing for IDEXX LABORATORIES INC /DE records an exercise / conversion involving Common Stock on November 7, 2025. The reported quantity was 5,405. The filing date is November 10, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- IDEXX LABORATORIES INC /DE
- Company CIK
- 0000874716
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 5,405
- Reported price
- 505.53
- Reference value
- 2,732,389.65
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 30,573.9435
- Ownership description
- Not reported
- SEC acceptance time
- Nov 10, 2025, 5:01 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Hunt Nimrata ↗
Executive Vice President
CIK 0001800619
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Includes 11 shares purchased under the Issuer Employee Stock Purchase Plan on September 30, 2025.
- F2
- Represents the weighted average price of the shares sold ranging from a low of $702.00 to a high of $703.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F3
- Represents the weighted average price of the shares sold ranging from a low of $703.05 to a high of $703.97 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F4
- Represents the weighted average price of the shares sold ranging from a low of $704.235 to a high of $705.175 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F5
- Represents the weighted average price of the shares sold ranging from a low of $705.26 to a high of $705.92 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F6
- Grant of option to buy shares of Issuer common stock that vested in four annual installments beginning February 14, 2021.
- F7
- Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2023.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.